Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements
This article was originally published in The Pink Sheet
Executive Summary
Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.
You may also be interested in...
Off-Label Promotion Settlement Includes Optional Preclearance Process
Amarin may submit up to two proposed communications annually about unapproved use of Vascepa, and FDA must respond with any concerns within 60 calendar days.
Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA
Court blesses combination of statements and disclosures that must accompany Vascepa promotions in a ruling that rejects FDA's narrow interpretation of 2012 Caronia case.
Off-Label Litigation: Amarin Sues FDA In Bid To Promote Vascepa Fish Oil
First Amendment lawsuit is most recent challenge of agency’s promotional policies.